This session highlights recent studies exploring the value of preoperative chemoradiation therapy in borderline resectable pancreatic cancer patients, the role of a radiation boost in rectal cancer, the role of chemoradiation therapy in gastric cancers treated preoperatively or postoperatively, the toxicities arising from esophageal cancer radiotherapy and hepatobiliary proton radiotherapy, the value of monitoring circulating tumor DNA in pancreatic cancer patients, and the possible additional benefit of adding a PARP inhibitor to radiation therapy for pancreatic cancer. Collectively, this session identifies gaps in knowledge in key clinical practice arenas in gastrointestinal cancer radiation therapy, provides attendees with a nuanced understanding of the range of management options available in these circumstance, advances novel paradigms in the management of GI cancers commonly treated with radiation therapy and provides attendees with the opportunity to determine if these paradigms might affect their day-to-day practice.
This activity is available from March 15, 2019, through 11:59 p.m. Eastern time on March 14, 2022.
This activity was originally recorded at ASTRO’s 2018 Best of ASTRO, November 30 - December 1, 2018 in San Francisco.
The meeting is designed to meet the interests radiation oncologists and radiation oncology residents.
- Define the role of preoperative chemoradiation therapy in borderline resectable pancreatic cancer
- Define the role of preoperative or postoperative chemoradiation therapy in gastric cancer
- Describe the causes and consequences of radiation-induced toxicity in esophageal and hepatobiliary cancers
Sunil Krishnan is employed by MD Anderson Cancer Center and receives compensation/remuneration/funding from the NIH, Department of Defense, Celgene and the Cancer Prevention and Research Institute of Texas. He holds a leadership position with the RTOG. He received royalties from the Taylor and Francis Group
Additionally, the SA-CME Task Force and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.